Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
IMRX
IMRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IMRX News
Immuneering Reports Promising Phase 2a Data for Metastatic Pancreatic Cancer Treatment
May 22 2026
NASDAQ.COM
Immuneering Reports Clinical Trial Data for Pancreatic Cancer
May 21 2026
Newsfilter
Immuneering Q1 Earnings Beat Expectations
May 15 2026
seekingalpha
Immuneering Reports New Data on Pancreatic Cancer Clinical Trials
May 15 2026
Newsfilter
Immuneering Presents Promising Data for Cancer Drug Atebimetinib
Apr 21 2026
NASDAQ.COM
Atebimetinib Shows Promising Results in Tumor Treatment
Apr 20 2026
Newsfilter
Immuneering Reports Q4 EPS Beat with Strong Cash Position
Mar 06 2026
seekingalpha
IMMUNEERING CORP SET TO RELEASE EXPANDED PANCREATIC CANCER COHORT DATA IN EARLY 2026
Mar 06 2026
moomoo
U.S. Stocks Rise on Venezuela Action; Chevron Shares Up 5.8%
Jan 10 2026
Benzinga
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
Jan 08 2026
Benzinga
Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026
Jan 08 2026
Benzinga
Immuneering Updates Pancreatic Cancer Trial Data, Survival Rates Show Significant Improvement
Jan 08 2026
Benzinga
Northrop Grumman Shares Rise 6.84% Following Military Budget Proposal
Jan 08 2026
Benzinga
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
Jan 08 2026
Benzinga
Immuneering Reports 64% Survival Rate in Phase 2a Trial for Pancreatic Cancer Drug
Jan 08 2026
NASDAQ.COM
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
Jan 07 2026
Benzinga
Show More News
